Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 101-00-8
2. Triisopropanolamine Cyclic Borate
3. Triisopropanolamine Borate
4. Borester 21
5. Boric Acid, Tris(1-amino-2-propyl) Ester
6. Nsc15099
7. Triisopropanolamine Cyclic Borate;borester 21; Nsc 15099
8. 2,8,9-trioxa-5-aza-1-borabicyclo(3.3.3)undecane, 3,7,10-trimethyl-
9. 2,8,9-trioxa-5-aza-1-borabicyclo[3.3.3]undecane, 3,7,10-trimethyl-
10. Nsc 15099
11. Ai3-61110
12. 2-propanol, 1,1',1''-nitrilotri-, Cyclic Borate
13. Mfcd03791298
14. 2-propanol, 1,1',1''-nitrilotri-, Borate
15. Dtxsid50905879
16. 3,7,10-trimethyl-4,6,11-trioxa-1-aza-5-borabicyclo[3.3.3]undecane
17. Nsc-15099
18. Wln: Z1y1&oboy1z1&oy1z1
19. Akos006229267
20. 2-propanol, 1,1',1''-nitrilotri-, Cyclic Ester With Boric Acid (h3bo3) (1:1)
21. 2-propanol, 1,1',1''-nitrilotri-, Cyclic Ester With Boric Acid (h3bo3) (1:1) (van)
22. As-72042
23. Db-058548
24. Cs-0015223
25. Ft-0645346
26. T2943
27. 2-propanol,1',1''-nitrilotri-, Cyclic Borate
28. D92646
29. A897267
30. J-200318
31. 2,9-trioxa-5-aza-1-borabicyclo[3.3.3]undecane, 3,7,10-trimethyl-
32. 2-propanol,1',1''-nitrilotri-, Cyclic Ester With Boric Acid (h3bo3) (1:1)
33. 27664-53-5
| Molecular Weight | 199.06 g/mol |
|---|---|
| Molecular Formula | C9H18BNO3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 0 |
| Exact Mass | 199.1379736 g/mol |
| Monoisotopic Mass | 199.1379736 g/mol |
| Topological Polar Surface Area | 30.9 Ų |
| Heavy Atom Count | 14 |
| Formal Charge | 0 |
| Complexity | 171 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 3 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A CT-001 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CT-001, including repackagers and relabelers. The FDA regulates CT-001 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CT-001 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A CT-001 supplier is an individual or a company that provides CT-001 active pharmaceutical ingredient (API) or CT-001 finished formulations upon request. The CT-001 suppliers may include CT-001 API manufacturers, exporters, distributors and traders.
CT-001 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CT-001 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CT-001 GMP manufacturer or CT-001 GMP API supplier for your needs.
A CT-001 CoA (Certificate of Analysis) is a formal document that attests to CT-001's compliance with CT-001 specifications and serves as a tool for batch-level quality control.
CT-001 CoA mostly includes findings from lab analyses of a specific batch. For each CT-001 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CT-001 may be tested according to a variety of international standards, such as European Pharmacopoeia (CT-001 EP), CT-001 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CT-001 USP).
LOOKING FOR A SUPPLIER?
